Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Executive Summary

FDA will have a total of 12 months to review 351(k) applications and additional time to schedule certain product development meetings under the Biosimilar User Fee Act II agreement; measures to enhance management of user fee resources and improve hiring will carry over from PDUFA VI.

Advertisement

Related Content

US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Biosimilars: Next User Fee Cycle Will Be Judged On US FDA's Approvals, Rep. Burgess Says
Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
Biosimilars Reviews Could Be Extended Two Months In BsUFA II

Topics

Advertisement
UsernamePublicRestriction

Register

PS119193

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel